arrow
M

Mina Lobbous

cleveland clinic brain tumor and neuro-oncology center
H指数:8
被引数:321

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CLTR-10 PHASE I/II STUDY OF STEREOTACTIC RADIOSURGERY WITH CONCURRENT OLAPARIB FOLLOWED BY ADJUVANT DURVALUMAB AND PHYSICIAN’S CHOICE SYSTEMIC THERAPY IN SUBJECTS WITH BREAST CANCER BRAIN METASTASES (SOLARA)

CLTR-10 I/II期研究:对于乳腺癌脑转移患者,进行立体定向放射手术联合奥拉帕利,随后进行辅助度伐利尤单抗和医生选择系统性治疗的临床研究(SOLARA)

2026-08-070
OA
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results

Tucatinib-曲妥珠单抗-卡培他滨治疗HER2乳腺癌女性软脑膜转移: TBCRC049 2期研究结果

2026-03-180
OAAI
IMG-72. [68Ga]Ga-DOTA-TATE PET as imaging biomarker for response assessment and monitoring in patients receiving [177Lu]Lu-DOTA-TATE for advanced intracranial meningioma

IMG-72. [68Ga]Ga-DOTA-TATE PET作为评估和监测接受[177Lu]Lu-DOTA-TATE治疗的颅内高级别脑膜瘤患者的影像学生物标志物

2025-11-110
OA
Targeting transsulfuration via suppression of thyroid hormone signaling: a modified phase 1/2 and pharmacodynamic trial of methimazole in patients with progressive WHO grade 4 gliomas

通过抑制甲状腺激素信号通路靶向转硫化:甲巯咪唑在进展性WHO IV级胶质瘤患者中的改良1/2期和药效学试验

2025-11-010
OAAI
Targeting macrophage migration inhibitory factor: A phase 2 and pharmacodynamic study of sitagliptin in patients with progressive grade 4 gliomas

靶向巨噬细胞移动抑制因子:西格列汀在进展性4级胶质瘤患者中的II期及药效学研究

2025-11-010
OAAI
RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF THE RADIOPHARMACEUTICAL [177LU]LU-DOTA-TATE IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA

单臂、开放标签、多中心II期研究中,放射性药物[177Lu]Lu-DOTATATE在成人晚期颅内脑膜瘤患者中的研究结果

2025-11-010
OAAI
Combinatorial targeting of avapritinib-driven MAPK activation in pediatric high-grade glioma

阿伐普利尼布诱导的MAPK激活在儿童高级别胶质瘤中的组合靶向治疗

2025-11-010
OAAI
A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209

一项关于佩米加替尼治疗经治胶质母细胞瘤或其他携带激活性FGFR1-3变异的胶质瘤的II期研究:FIGHT-209的最终结果

2025-10-010
OAAI
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib A Nonrandomized Clinical Trial

神经纤维瘤病1型皮肤神经纤维瘤的MEK抑制剂Selumetinib治疗:一项非随机临床试验

2025-02-260
PRE
Expedited chemoradiation after laser interstitial thermal therapy (LITT) is feasible and safe in patients with newly diagnosed glioblastoma

在激光间质热疗(LITT)后进行加速化放疗,对于新诊断胶质母细胞瘤患者是可行且安全的。

2025-02-140
OA
Intracerebral hemorrhage risk in glioma patients taking direct oral anticoagulants as compared with low molecular weight heparin

与低分子量肝素相比,直接口服抗凝剂在胶质瘤患者中的颅内出血风险

2025-01-010
OAAI
EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

PAXALISIB在新诊断和复发胶质母细胞瘤的GBM敏捷3期注册平台试验中的评估

2024-11-110
PRE